Skip to main content
Caplight Logo









10zyme

10zyme

Private
LondonHealthcare & Life Scienceshttps://10zyme.com/

Last Round

Accelerator

Nov 30, 2021

Total Funding Raised

$2,700

Momentum

Top 50%

of companies Caplight tracks

Company Overview

10zyme is a medical technology company developing a point-of-care self-test diagnostic for high-risk human papillomavirus (HPV) to improve cervical cancer screening accessibility.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Medical AI

Business Model

B2B2C

Customer Profile

Hardware Sales, Subscription SaaS

AI Layer

Infrastructure

Keywords

HPV self-testcervical cancer screeningpoint-of-care diagnosticsat-home HPV testsynthetic biologymedtechdiagnostic platformmachine learningDNAzymefemtechdigital healthhuman papillomavirusHPV

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

10zyme Comparables

Compare 10zyme with similar companies based on industry and business-model similarity.

10zyme comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
En Carta Diagnostics
71%
Teal Health
71%
Halodoc
69%

10zyme Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorNov 30, 2021

Key People

Founding team and executive leadership

Angela Pine

Founder & CEO

Founding Team

10zyme Investors

Notable investors and investment history

10zyme investors
InvestorRounds
Cancer Research HorizonsAccelerator
University of EdinburghAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors increased 67% MoM, reaching 2.6K.

  • Mar 2, 2026

    Monthly visitors grew 102% MoM, reaching 4K.

10zyme Filings

Explore SEC and related filing metadata, where available.

10zyme filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about 10zyme's valuation, stock price, and market status.

Is 10zyme a public or private company?

10zyme is a private company.

What is the current stock price of 10zyme?

10zyme is a private company with no public stock price. Caplight tracks 10zyme's secondary market activity and provides MarketPrice estimates to Caplight users.

How much is 10zyme worth (valuation)?

Valuation information for 10zyme is not publicly available.

Can I buy 10zyme stock?

10zyme shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was 10zyme's last funding round?

10zyme's most recent funding round was Accelerator on November 30, 2021.

Who are the main investors in 10zyme?

Key investors in 10zyme include Cancer Research Horizons, University of Edinburgh.

Will 10zyme IPO soon?

No public IPO plans have been announced for 10zyme.

How can I track 10zyme secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor 10zyme's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLondon
Employee Range5
Year Founded2023
Last FundingNov 30, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?